Hypoxia selects for a quiescent, CML stem/leukemia initiating-like population dependent on CBP/catenin transcription - PubMed (original) (raw)
Hypoxia selects for a quiescent, CML stem/leukemia initiating-like population dependent on CBP/catenin transcription
Aiko Kida et al. Curr Mol Pharmacol. 2013 Nov.
Abstract
Hypoxia has been reported to regulate both stem cell maintenance and differentiation. Wnt signaling is also a key regulator in stem cells. The recent discovery of functional cross-regulation between the Wnt pathway and HIF-1α/HIF-2α signaling further highlights the complexity of the role of hypoxia in the regulation of stem cells. In this report we reveal that human CML cell lines treated under hypoxic conditions increase the percentage of leukemia stem/initiating-like cells, as judged by surface marker expression, colony forming ability and quiescence. We demonstrate that differential usage of the Kat3 coactivators, CREBBP/Creb Binding Protein (CBP) and EP300 (p300) by catenin, with increased CBP/catenin signaling at the expense of p300/catenin signaling, is mechanistically correlated with the increase in the leukemia stem/initiating-like population. A specific small molecule inhibitor of CBP/catenin dependent transcription, ICG-001, can reverse these effects further demonstrating the critical involvement of CBP/catenin signaling in enhancing and maintaining the leukemia stem/initiating-like cell population under hypoxic conditions.
Similar articles
- CREB-binding protein, p300, butyrate, and Wnt signaling in colorectal cancer.
Bordonaro M, Lazarova DL. Bordonaro M, et al. World J Gastroenterol. 2015 Jul 21;21(27):8238-48. doi: 10.3748/wjg.v21.i27.8238. World J Gastroenterol. 2015. PMID: 26217075 Free PMC article. Review. - CBP/catenin antagonist safely eliminates drug-resistant leukemia-initiating cells.
Zhao Y, Masiello D, McMillian M, Nguyen C, Wu Y, Melendez E, Smbatyan G, Kida A, He Y, Teo JL, Kahn M. Zhao Y, et al. Oncogene. 2016 Jul 14;35(28):3705-17. doi: 10.1038/onc.2015.438. Epub 2015 Dec 14. Oncogene. 2016. PMID: 26657156 Free PMC article. - Characterization of Imatinib Resistant CML Leukemic Stem/Initiating Cells and Their Sensitivity to CBP/Catenin Antagonists.
Zhao Y, Wu K, Wu Y, Melendez E, Smbatyan G, Massiello D, Kahn M. Zhao Y, et al. Curr Mol Pharmacol. 2018;11(2):113-121. doi: 10.2174/1874467210666170919155739. Curr Mol Pharmacol. 2018. PMID: 28933312 - Small-molecule inhibition of CBP/catenin interactions eliminates drug-resistant clones in acute lymphoblastic leukemia.
Gang EJ, Hsieh YT, Pham J, Zhao Y, Nguyen C, Huantes S, Park E, Naing K, Klemm L, Swaminathan S, Conway EM, Pelus LM, Crispino J, Mullighan CG, McMillan M, Müschen M, Kahn M, Kim YM. Gang EJ, et al. Oncogene. 2014 Apr 24;33(17):2169-78. doi: 10.1038/onc.2013.169. Epub 2013 Jun 3. Oncogene. 2014. PMID: 23728349 Free PMC article. - Targeting CBP and p300: Emerging Anticancer Agents.
Masci D, Puxeddu M, Silvestri R, La Regina G. Masci D, et al. Molecules. 2024 Sep 24;29(19):4524. doi: 10.3390/molecules29194524. Molecules. 2024. PMID: 39407454 Free PMC article. Review.
Cited by
- CREB-binding protein, p300, butyrate, and Wnt signaling in colorectal cancer.
Bordonaro M, Lazarova DL. Bordonaro M, et al. World J Gastroenterol. 2015 Jul 21;21(27):8238-48. doi: 10.3748/wjg.v21.i27.8238. World J Gastroenterol. 2015. PMID: 26217075 Free PMC article. Review. - Disruption of Wnt/β-Catenin Exerts Antileukemia Activity and Synergizes with FLT3 Inhibition in _FLT3_-Mutant Acute Myeloid Leukemia.
Jiang X, Mak PY, Mu H, Tao W, Mak DH, Kornblau S, Zhang Q, Ruvolo P, Burks JK, Zhang W, McQueen T, Pan R, Zhou H, Konopleva M, Cortes J, Liu Q, Andreeff M, Carter BZ. Jiang X, et al. Clin Cancer Res. 2018 May 15;24(10):2417-2429. doi: 10.1158/1078-0432.CCR-17-1556. Epub 2018 Feb 20. Clin Cancer Res. 2018. PMID: 29463558 Free PMC article. - Role of hypoxia inducible factor-1 in cancer stem cells (Review).
Zhang Q, Han Z, Zhu Y, Chen J, Li W. Zhang Q, et al. Mol Med Rep. 2021 Jan;23(1):17. doi: 10.3892/mmr.2020.11655. Epub 2020 Nov 12. Mol Med Rep. 2021. PMID: 33179080 Free PMC article. Review. - Safely targeting cancer stem cells via selective catenin coactivator antagonism.
Lenz HJ, Kahn M. Lenz HJ, et al. Cancer Sci. 2014 Sep;105(9):1087-92. doi: 10.1111/cas.12471. Epub 2014 Sep 6. Cancer Sci. 2014. PMID: 24975284 Free PMC article. Review. - Enhanced Kat3A/Catenin transcription: a common mechanism of therapeutic resistance.
Bild A, Teo JL, Kahn M. Bild A, et al. Cancer Drug Resist. 2019;2(3):917-932. doi: 10.20517/cdr.2019.32. Epub 2019 Sep 19. Cancer Drug Resist. 2019. PMID: 32426696 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous